Novo Nordisk has launched a new late-stage trial for its experimental next-generation obesity drug candidate, CagriSema, as ...

Novo Nordisk ( NVO 6.12%) stock, maker of the blockbuster GLP-1 agonist weight-loss drugs Ozempic and Wegovy, jumped a lucky ...

Key Takeaways Novo Nordisk stock rose on Tuesday after the Financial Times reported that an activist investor is building a ...

Novo Nordisk's Q1 showed robust sales/EPS growth, fueled by soaring GLP-1 demand in a multi-billion dollar market. Read why I ...

Denmark-based multinational pharmaceutical company Novo Nordisk will make Wegovy, its approved weight-loss treatment for ...

Novo Nordisk (NVO) stock gains as the company launches a new Phase 3 trial for its next-gen weight loss drug CagriSema after ...

Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some ...

These companies own 97% of the weight loss drug market -- which could grow tenfold over the next decade -- and are developing ...

Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some ...

Health-care companies rose amid sales growth optimism. Drug-store chain CVS Health said it has seen complaints of strong push back from patients on its pharmacy-benefit manager's move to favor Novo ...

Teens are being prescribed Ozempic more than ever before — and some doctors are worried about what the trend could mean. In ...

STARING at yet another pregnancy test, Erica Coronado was thrilled but terrified. The 36-year-old had given up hope of a baby ...